5 Results for "

levodopa-induced dyskinesia

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "levodopa-induced dyskinesia" in MCE Product Catalog:

Cat. No.: HY-14859
CAS No.: 872363-17-2
Purity:  99.90%
Synonyms: ADX48621
Target:  

mGluR

Research Areas:  

Neurological Disease

Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-167899
CAS No.: 1835647-08-9
Target:  

mGluR

Research Areas:  

Neurological Disease

PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .
loading...
    loading...
Cat. No.: HY-176420
CAS No.: 3107596-27-7
Target:  

mGluR

Research Areas:  

Neurological Disease

VU6031545 is a potent mGlu 5 negative allosteric modulator with an IC50 of 15 nM. VU6031545 has excellent brain penetrant and oral bioavailability in rats .
loading...
    loading...
Cat. No.: HY-101008
CAS No.: 133399-65-2
3-MPPI is a GPCR ligand with high selectivity for α1-adrenergic receptor, with a Ki value of 0.21 nM for α1-adrenergic receptor and 50 nM for 5-HT1A receptor. 3-MPPI modulates the α1-adrenergic receptor signaling cascade. 3-MPPI is applicable to research related to hypertension, stress-induced anxiety-like behavioral responses, and levodopa-induced dyskinesia .
loading...
    loading...
Cat. No.: HY-182638
CAS No.: 1829530-11-1
Synonyms: CPL500036
Alofropodect is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). Alofropodect acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. Alofropodect alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. Alofropodect induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. Alofropodect can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia .
loading...
    loading...